Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS42000020EBVENSG00000122420.10protein_codingPTGFRNoNo5737P43088
TVIS42000021EBVENSG00000122420.10protein_codingPTGFRNoNo5737P43088
TVIS10032691HBVENSG00000122420.10protein_codingPTGFRNoNo5737P43088
TVIS20002754HPVENSG00000122420.10protein_codingPTGFRNoNo5737P43088
TVIS20010565HPVENSG00000122420.10protein_codingPTGFRNoNo5737P43088
TVIS20011236HPVENSG00000122420.10protein_codingPTGFRNoNo5737P43088
TVIS20048401HPVENSG00000122420.10protein_codingPTGFRNoNo5737P43088
TVIS20048060HPVENSG00000122420.10protein_codingPTGFRNoNo5737P43088
TVIS20047883HPVENSG00000122420.10protein_codingPTGFRNoNo5737P43088
TVIS20047818HPVENSG00000122420.10protein_codingPTGFRNoNo5737P43088
TCGA Plot Options
Drug Information
GenePTGFR
DrugBank IDDB00654
Drug NameLatanoprost
Target IDBE0000610
UniProt IDP43088
Regulation Typeagonist
PubMed IDs14646172; 25328381; 8922563
CitationsNakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y, Hara H: New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003 Dec;26(12):1691-5.@@Alm A: Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014 Sep 26;8:1967-85. doi: 10.2147/OPTH.S59162. eCollection 2014.@@Patel SS, Spencer CM: Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging. 1996 Nov;9(5):363-78. doi: 10.2165/00002512-199609050-00007.
GroupsApproved; Investigational
Direct ClassificationProstaglandins and related compounds
SMILESCC(C)OC(=O)CCCC=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Pathways
PharmGKBPA164774763
ChEMBLCHEMBL1051